Loading clinical trials...
Loading clinical trials...
Everolimus is an inhibitor of mammalian target of rapamycin, approved in patients with metastatic renal cell carcinoma. The objective of this study is to investigated the influence of everolimus immu...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Centre Hospitalier Universitaire de Besancon
NCT07540260 · Radiation Therapy, Metastatic Renal Cancer, and more
NCT07123090 · Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, and more
NCT06583070 · Radiation Therapy, Metastatic Renal Cancer, and more
NCT06959433 · Metastatic Renal Cancer
NCT01160445 · Metastatic Melanoma, Metastatic Renal Cancer
Centre Hospitalier Universitaire de Besançon
Besançon
Hôpital Nord Franche-Comté
Montbéliard
Hôpital Européen Georges Pompidou
Paris
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions